Charles River Laboratories CRL Stock
Charles River Laboratories Price Chart
Charles River Laboratories CRL Financial and Trading Overview
Charles River Laboratories stock price | 136.9 USD |
Previous Close | 207.42 USD |
Open | 207.06 USD |
Bid | 158 USD x 1000 |
Ask | 356 USD x 800 |
Day's Range | 206.09 - 209.74 USD |
52 Week Range | 181.22 - 262 USD |
Volume | 343.8K USD |
Avg. Volume | 527.97K USD |
Market Cap | 10.7B USD |
Beta (5Y Monthly) | 1.341197 |
PE Ratio (TTM) | 21.654922 |
EPS (TTM) | 0.21 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 249 USD |
CRL Valuation Measures
Enterprise Value | 13.63B USD |
Trailing P/E | 21.654922 |
Forward P/E | 17.284533 |
PEG Ratio (5 yr expected) | 2.47 |
Price/Sales (ttm) | 2.614122 |
Price/Book (mrq) | 3.4406283 |
Enterprise Value/Revenue | 3.332 |
Enterprise Value/EBITDA | 13.949 |
Trading Information
Charles River Laboratories Stock Price History
Beta (5Y Monthly) | 1.341197 |
52-Week Change | 2.37% |
S&P500 52-Week Change | 20.43% |
52 Week High | 262 USD |
52 Week Low | 181.22 USD |
50-Day Moving Average | 197.28 USD |
200-Day Moving Average | 213.33 USD |
CRL Share Statistics
Avg. Volume (3 month) | 527.97K USD |
Avg. Daily Volume (10-Days) | 389.3K USD |
Shares Outstanding | 51.18M |
Float | 50.61M |
Short Ratio | 2.38 |
% Held by Insiders | 0.97% |
% Held by Institutions | 99.00% |
Shares Short | 1.37M |
Short % of Float | 3.08% |
Short % of Shares Outstanding | 2.68% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | April 1, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 12.13% |
Operating Margin (ttm) | 16.41% |
Gross Margin | 36.74% |
EBITDA Margin | 23.88% |
Management Effectiveness
Return on Assets (ttm) | 5.68% |
Return on Equity (ttm) | 17.20% |
Income Statement
Revenue (ttm) | 4.09B USD |
Revenue Per Share (ttm) | 80.34 USD |
Quarterly Revenue Growth (yoy) | 12.59% |
Gross Profit (ttm) | 1.46B USD |
EBITDA | 977.24M USD |
Net Income Avi to Common (ttm) | 496.34M USD |
Diluted EPS (ttm) | 9.65 |
Quarterly Earnings Growth (yoy) | 10.90% |
Balance Sheet
Total Cash (mrq) | 201.59M USD |
Total Cash Per Share (mrq) | 3.94 USD |
Total Debt (mrq) | 3.17B USD |
Total Debt/Equity (mrq) | 100.38 USD |
Current Ratio (mrq) | 1.476 |
Book Value Per Share (mrq) | 60.736 |
Cash Flow Statement
Operating Cash Flow (ttm) | 626.39M USD |
Levered Free Cash Flow (ttm) | 258.57M USD |
Profile of Charles River Laboratories
Country | United States |
State | MA |
City | Wilmington |
Address | 251 Ballardvale Street |
ZIP | 01887 |
Phone | 781 222 6000 |
Website | https://www.criver.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 20000 |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Q&A For Charles River Laboratories Stock
What is a current CRL stock price?
Charles River Laboratories CRL stock price today per share is 136.9 USD.
How to purchase Charles River Laboratories stock?
You can buy CRL shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Charles River Laboratories?
The stock symbol or ticker of Charles River Laboratories is CRL.
Which industry does the Charles River Laboratories company belong to?
The Charles River Laboratories industry is Diagnostics & Research.
How many shares does Charles River Laboratories have in circulation?
The max supply of Charles River Laboratories shares is 49.12M.
What is Charles River Laboratories Price to Earnings Ratio (PE Ratio)?
Charles River Laboratories PE Ratio is 651.90470000 now.
What was Charles River Laboratories earnings per share over the trailing 12 months (TTM)?
Charles River Laboratories EPS is 0.21 USD over the trailing 12 months.
Which sector does the Charles River Laboratories company belong to?
The Charles River Laboratories sector is Healthcare.
Charles River Laboratories CRL included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
S&P 500 (Yahoo.com) GSPC | 5074.08 USD — |
-5.97
|
6.05B USD — | 5069.9 USD — | 5292.14 USD — | — - | 6.05B USD — |
S&P 500 INDEX SPX | 5074.08 USD — |
-5.97
|
1.8B USD — | 5069.9 USD — | 5292.14 USD — | — - | 1.8B USD — |
Dow Jones U.S. Biotechnology In DJUSBT | 2495.06 USD — |
-6.01
|
185.79M USD — | 2492.69 USD — | 2642.92 USD — | — - | 185.79M USD — |
Nasdaq US Smart Pharmaceuticals NQSSPH | 1331.01 USD — |
-5.6
|
— — | 1330.31 USD — | 1393.28 USD — | — - | — — |
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
NYSE COMPOSITE (DJ) NYA | 17618.61 USD — |
-6.12
|
— — | — — | — — | — - | — — |
Nasdaq US Price Setters Index NQPRCE | 2603.63 USD — |
-5.63
|
— — | 2600.97 USD — | 2724.21 USD — | — - | — — |
- {{ link.label }} {{link}}